VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist

被引：0

作者：

Chan, PS ^{[1
]}

Coupet, J ^{[1
]}

Park, HC ^{[1
]}

Lai, F ^{[1
]}

Hartupee, D ^{[1
]}

Cervoni, P ^{[1
]}

Dusza, JP ^{[1
]}

Albright, JD ^{[1
]}

Ru, X ^{[1
]}

Mazandarani, H ^{[1
]}

Tanikella, T ^{[1
]}

Shepherd, C ^{[1
]}

Ochalski, L ^{[1
]}

Bailey, T ^{[1
]}

Lock, TYW ^{[1
]}

Ning, XP ^{[1
]}

Taylor, JR ^{[1
]}

Spinelli, W ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Princeton, NJ 08543 USA

来源：

VASOPRESSIN AND OXYTOCIN: MOLECULAR, CELLULAR, AND CLINICAL ADVANCES | 1998年 / 449卷

关键词：

D O I：

暂无

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

引用

页码：439 / 443

页数：5

共 50 条

[21] SELECTIVE VASOPRESSIN V2 RECEPTOR ANTAGONIST DRUGS FOR PATIENTS WITH CIRRHOSIS AND ASCITES
Chavez-Tapia, N. C.
Barrientos-Gutierrez, T.
Santiago-Hernandez, J. J.
Tellez-Avila, F.
Mendez-Sanchez, N.
Uribe, M.
JOURNAL OF HEPATOLOGY, 2012, 56 : S265 - S265
[22] Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure
Veeraveedu, Punniyakoti T.
Watanabe, Kenichi
Ma, Meilei
Palaniyandi, Suresh S.
Yamaguchi, Ken'ichi
Suzuki, Kenji
Kodama, Makoto
Aizawa, Yoshifusa
BIOCHEMICAL PHARMACOLOGY, 2007, 74 (10) : 1466 - 1475
[23] Synthesis and structure-activity relationships (SAR) of pyrrolobenzodiazepines related to the potent selective orally active nonpeptide vasopressin V2 receptor agonist VNA-932.
Ashwell, MA
Bagli, JF
Caggiano, TJ
Chan, PS
Dusza, JP
Dushin, RG
Failli, AA
Molinari, AJ
Park, CH
Rodgers, JF
Shumsky, JS
Trybulski, EJ
Williams, DK
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U38 - U38
[24] The effects of VPA-985, a vasopressin receptor antagonist, on water metabolism in patients with hyponatremia: A multi-center randomized placebo controlled trial.
Wong, F
Blei, AT
Blendis, LM
Robertson, GL
Thuluvath, PT
GASTROENTEROLOGY, 2000, 118 (04) : A980 - A981
[25] OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist
1600, (252):
[26] Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan
Furukawa M.
Umehara K.
Kashiyama E.
Cardiovascular Drugs and Therapy, 2011, 25 (Suppl 1) : S83 - S89
[27] Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V-2 receptor antagonist
SerradeilLeGal, C
Lacour, C
Valette, G
Garcia, G
Foulon, L
Galindo, G
Bankir, L
Pouzet, B
Guillon, G
Barberis, C
Chicot, D
Jard, S
Vilain, P
Garcia, C
Marty, E
Raufaste, D
Brossard, G
Nisato, D
Maffrand, JP
LeFur, G
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (12): : 2729 - 2738
[28] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
Risvanis, J
Naitoh, M
Johnston, CI
Burrell, LM
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
[29] Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V(1A) and V2 receptor antagonist
Tahara A.
Saito M.
Sugimoto T.
Tomura Y.
Wada K.
Kusayama T.
Tsukada J.
Ishii N.
Yatsu T.
Uchida W.
Tanaka A.
Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 357 (1) : 63 - 69
[30] Pharmacological characterization of YMO87, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist
Tahara, A
Saito, M
Sugimoto, T
Tomura, Y
Wada, K
Kusayama, T
Tsukada, J
Ishii, N
Yatsu, T
Uchida, W
Tanaka, A
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (01) : 63 - 69

← 1 2 3 4 5 →